Non-Hodgkin's lymphoma in the elderly
Thrombopoietin stimulates ex vivo expansion of mature neutrophils in the early stages of differentiation
Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia—a randomized, placebo-controlled, double-blind safety and efficacy study
Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia
Mutations of the 5′ noncoding region of the BCL-6 gene in primary bone lymphomas
Triplication (/αααAnti3.7) or deletion (-α3.7/) association in Argentinian β-thalassemic carriers
Immunosuppressive therapy with antithymocyte globulin and cyclosporine for prolonged marrow failure after hemophagocytic syndrome
Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease
Therapy-related leukemia cutis
Subtotal splenectomy for the treatment of chronic lymphocytic leukemia
Severe factor X deficiency treated with heparin-added prothrombin complex concentrate
Late relapse of non-Hodgkin's lymphoma after a 28-year disease-free interval
Demyelination in the brain as a paraneoplastic disorder
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)
November 2003